Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clodronate

J A Kanis1, E V McCloskey

  • 1World Health Organization Collaborating Centre for Metabolic Bone Diseases, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, United Kingdom.

Cancer
|November 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of FRAXplus adjustments on fracture risk reclassification in older Swedish women-results from the SUPERB-study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

A surrogate FRAX model for Mongolia.

Archives of osteoporosis·2025
Same author

Conflating the Operational Definition of Osteoporosis with Intervention Thresholds.

Calcified tissue international·2025
Same author

A surrogate FRAX model for Nepal.

Archives of osteoporosis·2024
Same author

An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.

Journal of endocrinological investigation·2023
Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same journal

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same journal

Bendamustine in indolent lymphoma: Letting the dust settle down.

Cancer·2026
Same journal

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Cancer·2026
Same journal

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

Cancer·2026
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
See all related articles

Clodronate effectively inhibits bone resorption and manages hypercalcemia in various cancers. It reduces bone pain, fractures, and skeletal complications, improving patient quality of life.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Clodronate is a second-generation bisphosphonate.
  • It inhibits bone resorption without impairing mineralization.
  • Available in oral and intravenous forms, it is widely used for hypercalcemia.

Purpose of the Study:

  • To evaluate the efficacy of clodronate in managing hypercalcemia and skeletal complications in cancer patients.
  • To assess the impact of clodronate on bone pain and osteolytic bone disease.
  • To determine if clodronate can prevent skeletal morbidity and modify disease progression.

Main Methods:

  • Review of therapeutic regimens for clodronate in hypercalcemia (IV 300 mg for 5 days or 1500 mg single infusion).
  • Analysis of placebo-controlled studies on bone pain in the absence of hypercalcemia.

Related Experiment Videos

  • Evaluation of double-blind, prospective, controlled studies on skeletal morbidity in breast carcinoma and myelomatosis.

    • Main Results:

    • Clodronate is effective in hypercalcemia, with efficacy varying by cancer type and skeletal metastases.
    • Significant decreases in bone pain were observed in placebo-controlled studies.
    • Studies showed significant reductions in bone pain, fractures, and hypercalcemia in breast carcinoma and myelomatosis patients.
    • Long-term oral clodronate decreased skeletal morbidity and the number of skeletal metastases in recurrent breast carcinoma.

    Conclusions:

    • Clodronate is an effective treatment for hypercalcemia and skeletal complications in cancer.
    • It significantly reduces bone pain and the incidence of fractures and hypercalcemia.
    • Clodronate may modify the natural history of skeletal disease expression, improving patient quality of life.